Valopicitabine

N/A

Report date: 2022/07/19 20:00:45
NME

Base Information

Drug NameValopicitabine
Drug Alias Name伐洛他滨valopicitabina缬西他滨valopicitabinumval-mCyd +[7] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives
Mechanisms of ActionHepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors
TargetsHepatitis C virus NS5B RNA-dependent RNA polymerase
Therapy Area/IndicationsHepatitis C, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPuerto Rico
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma AgMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis Pharma AgMerck Sharp & Dohme LLC
Active IndicationsN/A
Inactive IndicationsHepatitis C, Chronic

Other Information

ATC CodeN/A
Related LinksKEGG